LAIPLA's Patents On Tap

The past several years have seen significant, diverse legislative developments and agency actions that affect the value of patent rights for life sciences companies, including:

• Regulation of drug pricing at the federal and state level, from drug pricing boards to the IRA
• FTC challenges to Orange Book listings
  AI policy at the USPTO
• Legislation affecting collaborations (e.g., the BIOSECURE Act)

The LAIPLA Patent Committee’s informative panel will cover:

• The current administration’s approach to patent rights – what’s new(ish), and what you need to know now.
• How the election might change the landscape (or not).
• Best practices for preparing for and managing risk.

Natasha Daughtrey will be a featured panelist on LAIPLA's panel, "To November & Beyond: Protecting and Leveraging Biopharma Patent Rights."